Abstract: In 49 patients that followed-up a median 10 months later, HIV drug resistance mutations at >20% frequency such as K103N, M184VI and P225H still existed, but with decreased frequencies.
Result: Although these variants still existed at follow-up, the frequencies of the mutations M184VI, K103N and P225H decreased over time, and most of them remained at frequencies of more than 20%.
Result: At baseline, mutations with a frequency of 20% and above were NRTI-related, such as M184VI (2.0%, 1/49), and NNRTI-related like K103N (14.3%, 7/49), E138AG (4.1%, 2/49),
Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes.
PMID: 33649107
2021
Antimicrobial agents and chemotherapy
Introduction: Likewise, cases of failure with emergent M184V and R263K were reported for DTG-plus-lamivudine dual therapy in the clinical trials GEMINI and ACTG5353.
Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa.
Abstract: Several RTI RAMs, such as K65R, M184V or K103N and PI RAM V82A, were identified in < 20% of the population.
Abstract: The majority of the drug resistance mutations in the minor viral quasispecies were observed in the V82A mutation (n = 13) in protease and K65R (n = 5), K103N (n = 7) and M184V (n = 5) in reverse transcriptase.
Result: Most of the DRMs in the minor viral quasispecies were observed in V82A mutation (n = 13) in protease and K65R (n = 5),
First Assessment of Acquired HIV-1 Drug Resistance and Mutation Patterns in Suriname.
PMID: 33287618
2021
AIDS research and human retroviruses
Abstract: The most common DRMs were M184V (23.6%) and K103N (18.8%).
Prevalence and Molecular Epidemiology of Transmitted Drug Resistance and Genetic Transmission Networks Among Newly Diagnosed People Living With HIV/AIDS in a Minority Area, China.
Result: M184MI/V (0.38%) was the most prevalent NRTI-associated mutation, followed by T215F/L (0.30%).
Discussion: Although it is still debatable whether continued use of 3TC provides actual benefit, it is still lacking a fully active multitherapy in the presence of the M184V mutation, which would lead to a greater risk for virologic failure and may be related to higher TDR in newly diagnosed PLWH.
Discussion: It is reported that the M184MI/V mutation showed a high- and intermediate-level resistance to 3TC that reduces the replicative capacity of reverse transcriptase.
Discussion: Our study found that the two NRTI mutations (M184MI/V and M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
PMID: 33076683
2021
AIDS research and human retroviruses
Abstract: Conclusions: In patients with HIV and the M184V mutation, the PI + INI ART has shown a greater decrease in control VL and, thus, a good virological response.
Abstract: Introduction: In patients with HIV in antiretroviral treatment (ART) and virological failure to the first-line regimen, establishing a therapeutic regimen after having identified the M184V mutation, which confers ART resistance, represents a dilemma.
Abstract: Methods: A retrospective cohort study was developed based on the information of the HIV program participants with the M184V mutation.
Abstract: Objective: To compare the virological response of the therapeutic regimens prescribed to patients with HIV who presented the M184V mutation in two national hospitals in Lima, Peru, during the y
Determination of reverse transcriptase inhibitor resistance mutations in HIV-1 infected children in Cote d'Ivoire.
Abstract: Frequently encountered resistance mutations were for NRTIs: M184V (88%), TAMs (67%), T215F/I/V/Y (33%), and L74I/V (24%); for NNRTIs: K103N/S (74%), P225H (26%), and G190A/E/Q (24%).
Simulating HIV Breakthrough and Resistance Development During Variable Adherence to Antiretroviral Treatment.
PMID: 33196554
2021
Journal of acquired immune deficiency syndromes (1999)
Abstract: MT-2 cells were infected with wild-type or low frequency M184V HIV-1, exposed to drug combinations, monitored for VB, and rebound virus was deep sequenced.
Abstract: RESULTS: Cultures infected with wild-type or low frequency M184V HIV-1 showed no VB with BIC+FTC+TAF at drug concentrations corresponding to Cmin, Cmin - 1, or Cmin - 2 but breakthrough did occur in 26 of 36 cultures at Cmin - 3, where the M184V variant emerged in one culture.
Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study.
PMID: 33200210
2021
The Journal of antimicrobial chemotherapy
Abstract: Baseline proviral DNA NGS detected lamivudine RAMs (M184V/I and/or K65R/E/N) above a 5% threshold in 71.4% (15/21) and 15% (3/20) of participants with and without history of lamivudine resistance, respectively.
Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study.
Result: M184V and M184I were detected in seven and 18 samples respectively, the latter generally as a low-level variant (2-5%).
Discussion: The M184VI may also be linked with other DRMs and tends to wane over time due to overgrowth of more replication competent wild-type virus.
Discussion: The detection of some DRMs predominately at low levels is likely due to impaired viral fitness, which has been described for mutations such as M184VI and D30N.
Discussion: The most commonly detected NRTI DRMs, K219QENR and M184VI, occurred predominately as minor variants while the majority of patients with T215 revertants had the mutation in > 80% of the quasispecies.
HIV mutation literature information.
PMID: 
2021
Pathogens (Basel, Switzerland)
Browser Board
Co-occurred Entities
Filtrator
ViMRT